ABL1 Fusion

CI-VAR-00001158Explore in graph →CIViC 1

Curated evidence

Evidence by cancer (464 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 451–464 of 464 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm14
BCR::ABL1 Fusion AND ABL1 H396P	Imatinib	Predictive	D	Supports Resistance	3	accepted	EID7847 In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib treatment (IC50: >2000.0 nM) as compared t… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 H396P	Bafetinib + NilotinibSubstitutes	Predictive	D	Does Not Support Resistance	3	accepted	EID7846 In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib (INNO-406) treatme… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.